Can-Fite’s upfront and royalties on sales upon regulatory approval of Piclidenoson for veterinary use, is projected to be $325 million in the ...

Over the past two decades, I’ve observed significant shifts in the life sciences, pharmaceutical, and CDMO landscape. Pharmaceutical companies and their outsourcing partners must continuously ...

Delivering late stage therapeutic pipeline, building the next generation of radiopharmaceuticals, growing industry leading precision medicine business, expanding global infrastructure for product ...